Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Sysmex instrumentation helps optimise clinical trial performance

Sysmex America : 24 May, 2007  (New Product)
Sysmex America's instrument technology has been actively involved with Genzyme in the company's multinational Phase II clinical drug trial programme.
Application of the newly available IPF parameter (Immature Platelet Fraction), a reticulated platelet equivalent, is an additional reason for the inclusion of Sysmex XE 2100 instruments into the clinical trial arena.

The IPF parameter is a direct extension of the fluorescent optical platelet count, available on Sysmex automated cell counters, due to the use of proprietary Polymethine fluorescent dyes with nucleic acid affinity.

This fluorescence flow cytometry is applied to all cells analysed on the XE2100 instrument, and is responsible for the enhanced analytical sensitivity that is being appreciated by both routine laboratories, and clinical research institutions.

The ability to accurately quantify immature cells (Immature Granulocytes, Reticulocytes, and Immature Platelets) is a feature of Sysmex reagent technology that is becoming increasingly attractive from the clinical research perspective, since immature cells more acutely reflect changes that occur in response to drug administration or changes in disease progression.

Clinical applications of the IPF parameter include differentiation between thrombocytopenia due to bone marrow suppression, and thrombocytopenia due to peripheral platelet destruction.

Contracts were recently signed which enable a research collaboration between Sysmex and Genzyme using samples from Genzyme's multinational Phase II clinical drug trial.

The trial involves investigating the treatment efficacy of the drug alemtuzumab in patients with early, active relapsing-remitting Multiple Sclerosis.

This is the first of many potential clinical trial applications of the IPF parameter.
ITP treatment options include: IVIG, Anti-D and steroids, to prevent peripheral destruction of platelets; and newer therapies that induce thrombopoiesis.

A presentation on the use of the Sysmex XE 2100 instrument Immature Platelet Fraction was recently presented at the International Society of Laboratory Hematology (ISLH) meeting in Miami, Florida, USA, by Genzyme's Dr Mark Goldberg, senior vice president clinical research.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo